EVANSTON, Ill., Dec. 28, 2017 /PRNewswire/ — Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced that Norbert Riedel, Ph.D., president and chief executive officer, will present at the 36th…
